<DOC>
	<DOCNO>NCT02072967</DOCNO>
	<brief_summary>Prospective multicenter observational non-interventional study ass routine clinical practice Bendamustine use second line therapy relapse refractory indolent B-cell non-Hodgkin 's lymphoma</brief_summary>
	<brief_title>Ribomustin Second Line Therapy Relapsed Refractory Indolent B-cell Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Doctor 's decision prescribe Ribomustin rituximab combine therapy treatment relapse refractory indolent Bcell NonHodgkin 's Lymphoma ( iNHL ) Informed Consent Form personal data handle sign program participant , authorized Independent Ethics Committee Eastern Cooperative Oncology Group ( ECOG ) status &lt; 2 . Confirmed relapse disease progression Bcell CD20+ NonHodgkin 's Lymphoma ( lymphocytic , lymphocytoplasmocytic , follicular , marginal zone ) minimum one line iNHL treatment Patients relapse refractory indolent Bcell NonHodgkin 's Lymphoma current plan Ribomustin rituximab combine therapy follow rituximab maintenance therapy Indolent NonHodgkin 's Lymphoma transformation Lymphoma central nervous system ( CNS ) involvement Presence second malignant tumor . Currently participate clinical trial , and/or take investigational drug within 28 day prior enrollment . Contraindications Ribomustin usage accordance product label Contradictions rituximab usage accordance product label</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
	<keyword>Non-Hodgkin Lymphoma</keyword>
	<keyword>Bendamustine</keyword>
</DOC>